The partnership’s main focus is on developing the nasally delivered mRNA vaccine targeting influenza. Credit: mi_viri/Shutterstock.

Ethris has partnered with contract development and manufacturing organisation Lonza for the development of room-temperature stable mRNA vaccine candidates targeting respiratory conditions.

The collaboration focuses on creating spray-dried formulations of vaccines tailored for mucosal delivery.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The partnership’s main aim is to develop the nasally delivered mRNA vaccine targeting influenza.

It is a non-invasive method that aims to offer localised immune responses and could be instrumental in decreasing the transmission of viruses by establishing mucosal immunity at the entry point of the virus.

Lonza is set to offer spray-drying and particle engineering for the vaccines based on a stabilised non-immunogenic mRNA and stabilised lipid nanoparticles platform of Ethris at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend, US.

Formulations will be developed at the site in line with current good manufacturing practice standards.

The partnership is part of Ethris’ strategy to create mucosal mRNA vaccines that remain stable at room temperature.

This initiative is supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and includes the development of the first influenza vaccine candidate.

Ethris CEO Dr Carsten Rudolph stated: “Lonza’s support and leading expertise are an asset and provide unique support as we progress development of our mRNA vaccine technology under the CEPI grant.

“Together, I believe we are well positioned to create promising non-invasive mucosal vaccine candidates that could potentially transform how respiratory diseases are prevented globally.”

In June 2024, Ethris reported initial positive Phase I data for its intranasal mRNA vaccine candidate, ETH47.

mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.